Topics
Diffuse midline glioma | Treatment | Targeted therapy | Dordaviprone (ONC201)
Home > Publications > Topics > Diffuse midline glioma > Treatment > Targeted therapy > Dordaviprone (ONC201)
Hansford JR, Manoharan N, Bouche G, Ramaswamy V, Jabado N, Bouffet
E.
ONC201 (Dordaviprone): review of
evidence to date in diffuse midline glioma, hope or hype?
Expert
Opin Emerg Drugs. 2024 Nov 21:1-5. doi:
10.1080/14728214.2024.2426649. PMID:
39548664. Perspective. ˍ
Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE,
Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot
J, Dixit KS, Graber JJ, Haggiagi AM, Harrison RA, Kheradpour A,
Kilburn L, Kurz SC, Lu G, MacDonald TJ, Mehta M, Melemed AS,
Nghiemphu PL, Ramage SC, Shonka N, Sumrall A, Tarapore R, Taylor
L, Umemura Y, Wen PY.
ONC201
(Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline
Glioma.
J
Clin Oncol. 2024 Feb 9:JCO2301134. doi:
10.1200/JCO.23.01134. PMID:
38335473. Interventional study. ˍ